Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THC-induced Immune-genome Changes in HIV
NCT04920539Phase 1Completed
- Sponsor
- Yale University
- Start
- Feb 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dronabinol, sponsored by Yale University. Primary endpoints: Change in Gene Expression Alteration and Change in Cytokine Profile. Started Feb 2022; status: completed.
02
Drugs
dronabinol
Beyond the preview
Go deeper on NCT04920539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920539.